Beacon Therapeutics today announced a key milestone in its mission to develop transformative treatments for inherited retinal disorders, having dosed the first patient in its Phase 1/2 LANDSCAPE clinical trial. The study is evaluating laru-zova (BEACON-101), an investigational gene therapy for X-linked retinitis pigmentosa (XLRP)caused by RPGR mutations.

The open-label, dose-escalation LANDSCAPE trial is enrolling adult participants with genetically confirmed XLRP. Laru-zova is delivered via a single subretinal injection aimed at introducing a functional copy of the RPGR gene into affected retinal cells. The trial will primarily assess safety and tolerability, with secondary endpoints evaluating retinal structure and function over time. Early clinical observations will guide dose selection and support progression to later stages of development.

“Dosing the first patient in the LANDSCAPE trial represents an important step forward in our efforts to address the underlying genetic cause of XLRP,” said a spokesperson of Beacon Therapeutics. “We are committed to advancing innovative therapies that have the potential to preserve vision and improve quality of life for patients facing this progressive disorder.”

XLRP is a progressive inherited retinal disorder that causes photoreceptor degeneration, tunnel vision, and eventual severe vision loss. RPGR mutations are among the most common causes of X-linked forms of the disease, with limited treatment options currently available. Beacon’s gene therapy is designed to target the root genetic cause, offering a potential therapeutic approach beyond symptomatic management.